Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

Core Insights - Greenwich LifeSciences Inc. reported a significant reduction in breast cancer recurrence rates in its Phase 3 trial FLAMINGO-01, with an approximately 80% reduction observed in the non-HLA-A02 patient group [1][2] - The trial results are consistent with previous Phase 2b trial findings, where HLA-A02 patients also showed up to an 80% reduction in recurrence rates compared to 20-50% reductions from other approved treatments [2] - The company has noted that the immune response and safety profile in non-HLA-A02 patients are trending similarly to those in the HLA-A02 group and the Phase 2b study [3] Trial Details - The Primary Immunization Series (PIS) consists of six GLSI-100 injections over the first six months, followed by five booster injections every six months to enhance long-term immune response [4] - In the non-HLA-A*02 data set, 250 patients received GLSI-100, which is five times the number treated in the Phase 2b trial, providing more robust recurrence rate data [4] Market Reaction - Following the announcement, GLSI stock increased by 8.76%, reaching $11.67 [5]